Therapeutic Evaluation of Alpha Lipoic Acid for Geographic Atrophy

About the Research Project
Program
Award Type
Bold Ideas initiatives
Award Amount
$130,000
Active Dates
January 01, 2016 - June 30, 2019
Grant ID
CM2016971
Co-Principal Investigator(s)
Joshua Dunaief, MD, PhD, University of Pennsylvania
Maureen Maguire, University of Pennsylvania
Goals
The blinding lesions of the geographic atrophy (GA) form of advanced age-related macular degeneration (AMD) are responsible for 20 percent of legal blindness in North America. Research has shown that oxidative stress and iron overload at the retina are major contributors to these atrophic lesions in AMD, consisting of localized areas of dead cells.
Currently, there is no treatment available; however, there is interest in a potent antioxidant and iron chelator called alpha lipoic acid. A chelating agent is a substance whose molecules can form several bonds to a single metal ion, thus suppressing its chemical activity. Alpha lipoic acid is found in many food sources, including spinach, broccoli, and potatoes; it also is manufactured for use as a supplement. Through a Phase II pilot clinical trial, we are testing alpha lipoic acid as a treatment for GA.
Related Grants
Macular Degeneration Research
Cellular Scale Measures of Short-Term Retinal Atrophy Progression
Active Dates
October 01, 2022 - September 30, 2025

Principal Investigator
Kristen Bowles Johnson, PhD, OD
Current Organization
Indiana University
Macular Degeneration Research
Investigating Multiarmed Cell Death (PANoptosis) in Dry AMD Progression
Active Dates
July 01, 2022 - June 30, 2025

Principal Investigator
Lucia Celkova, PhD
Current Organization
Trinity College Dublin (Ireland)
Macular Degeneration Research
Elucidating How Smoking Causes Advanced Age-Related Macular Degeneration
Active Dates
September 01, 2020 - November 30, 2022

Principal Investigator
Claudio Punzo, PhD
Current Organization
University of Massachusetts School of Medicine